Conflict of interest in psychopharmacology: Can Dr. Jekyll still control Mr. Hyde?

Psychotherapy and Psychosomatics

Volumn 73, Issue 1, 2004, Pages 1-4

  Fava, Giovanni A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; MEDICAL EDUCATION; MEDICAL LITERATURE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PUBLICATION; SCIENTIFIC LITERATURE;

BIOMEDICAL AND BEHAVIORAL RESEARCH; HEALTH CARE AND PUBLIC HEALTH; MENTAL HEALTH THERAPIES;

CONFLICT OF INTEREST; DRUG INDUSTRY; EDITORIAL POLICIES; EVIDENCE-BASED MEDICINE; HUMANS; PSYCHOPHARMACOLOGY; PUBLISHING; SOCIAL RESPONSIBILITY;

EID: 0347383865     PISSN: 00333190     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074433     Document Type: Editorial

References (40)

1. Krimsky S: Journal policies on conflict of interest: If this is the therapy, what's the disease? Psychother Psychosom 2001;70:115-117.
2. Krimsky S, Rothenberg LS, Stott P, Kyle G: Scientific journals and their authors' financial interests. Psychother Psychosom 1998;67:194-201.
3. Fava GA: Conflict of interest and special interest groups. Psychother Psychosom 2001;70:1-5.
4. Fava GA: Holding on: Depression, sensitization by antidepressant drugs, and the prodigal experts. Psychother Psychosom 1995;64:57-61.
5. Kundera M: La lenteur. Paris, Gallimard, 1995.
6. Macedo D (ed): Chomsky on MisEducation. Lanham, Rowman and Littlefield, 2000.
7. Marks IM, Swinson RP, Basoglu M, Kuch K, Noshirvani H, O'Sullivan G, Lelliott PT, Kirby M, McNamee G, Sengun S, Wickwire K: Alprazolam and exposure alone and combined in panic disorder with agoraphobia. Br J Psychiatry 1993;162:776-787.
8. Basoglu M: Pharmacological and behavioral treatment of panic disorder. Psychother Psychosom 1992;58:57-59.
9. Fava GA: All our dreams are sold. Psychother Psychosom 1998;67:191-193.
10. Healy D, Thase ME: Is academic psychiatry for sale? Br J Psychiatry 2003;182:388-390.
11. Starcevic V: Opportunistic 'rediscovery' of mental disorders by the pharmaceutical industry. Psychother Psychosom 2002;71:305-310.
12. Petersen M: Undisclosed financial ties prompt reproval of doctor. New York Times, Aug 3, 2003.
13. Kuhn TS: The Structure of Scientific Revolutions, ed 2. Chicago, The University of Chicago Press, 1970.
14. Schmidt ME, Fava M, Zhang S, Gonzales J, Raute NJ, Judge R: Treatment approaches to a major depressive disorder relapse. 1. Dose increase. Psychother Psychosom 2002;71:190-194.
15. Fava M, Schmidt ME, Zhang S, Gonzales J, Raute NJ, Judge R: Treatment approaches to a major depressive disorder relapse. 2. Reinitiation of antidepressant treatment. Psychother Psychosom 2002;71:195-199.
16. Baldessarini RJ, Ghaemi SN, Viguera A: Tolerance in antidepressant treatment. Psychother Psychosom 2002;71:177-179.
17. Ananth J, Venkatesh R, Burgoyne K, Gunatilake S: Atypical antipsychotic drug use and diabetes. Psychother Psychosom 2002;71:244-254.
18. Healy D: Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 2003;72:71-79.
19. Rihmer Z: Do SSRI increase the risk of suicide among depressives even if they are taking only placebo? Psychother Psychosom 2003;72:357-358.
20. Benazzi F: Do SSRIs cause suicide? Psychother Psychosom 2003;72:358-359.
21. Healy D: Reply. Psychother Psychosom 2003;72:359-360.
22. Balon R: SSRIs and suicide: Is the evidence, as with beauty, in the eye of the beholder? Psychother Psychosom 2003;72:293-299.
23. Faravelli C, Cosci F, Ciampelli M, Scarpato MA, Spiti R, Ricca V: A self-controlled, naturalistic study of selective serotonin reuptake inhibitors versus tricyclic antidepressants. Psychother Psychosom 2003;72:95-101.
24. Bahl S, Cotterch M, Kreiger N: Use of antidepressant medications and the possible association with breast cancer risk. Psychother Psychosom 2003;72:185-194.
25. Svensson S, Mansfield PR: Escitalopram: Superior to citalopram or a chiral chimera? Psychother Psychosom 2004;73:10-16.
26. Cooper B: Evidence-based mental health policy: A critical appraisal. Br J Psychiatry 2003;183:105-113.
27. Feinstein AR: Meta analysis: Statistical alchemy for the 21st century. J Clin Epidemiol 1995;48:71-79.
28. Otto MW, Nierenberg AA: Assay sensitivity, failed clinical trials, and the conduct of science. Psychother Psychosom 2002;71:241-243.
29. Lexchin J, Bero A, Djulbegovic B, Clark O: Pharmaceutical industry sponsorship and research outcome and quality. BMJ 2003;326:1167-1176.
30. Bekelman JE, Li Y, Gross CP: Scope and impact of financial conflict of interest in biomedical research. JAMA 2003;289:454-465.
31. Melander H, Ahlquist-Rastad J, Beermann B: Evidence b(i)ased medicine - Selective reporting from studies sponsored by pharmaceutical industry. BMJ 2003;326:1171-1175.
32. Thornton A, Lee P: Publication bias in meta-analysis. J Clin Epidemiol 2000;53:207-216.
33. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM: Relapse prevention with antidepressant drug treatment in depressive disorders. Lancet 2003;361:653-661.
34. Fava GA: Long-term treatment with antidepressant drugs: The spectacular achievements of propaganda. Psychother Psychosom 2002;71:127-132.
35. Sensky T: The utility of systematic reviews. Psychother Psychosom 2003;72:171-175.
36. Feinstein AR: The intellectual crisis in clinical science: Medaled models or muddled mettle. Perspect Biol Med 1987;30:215-230.
37. Karger T, Karger S: Some thoughts from your publisher. Psychother Psychosom 2002;71:63.
38. Horwitz RI, Singer BH, Makuch RW, Viscoli CM: Can treatment that is helpful on average be harmful to some patients? J Clin Epidemiol 1996;49:395-400.
39. Engel GL: Clinical observation. The neglected basis method of medicine. JAMA 1965;192:849-852.
40. Balon R: Reflections on relevance: Psychotherapy and Psychosomatics in 2003. Psychother Psychosom 2004;73:5-9.